Status:
UNKNOWN
High-dose Chemotherapy With Autologous Stem Cell Rescue in Pediatric High-risk Brain Tumors
Lead Sponsor:
Samsung Medical Center
Collaborating Sponsors:
KSPNO stem cell transpantation committee
Conditions:
Brain Tumor
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
* Study No.: KSPNO-S-081 Reduced-dose Craniospinal Radiotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Rescue in Children with Newly Diagnosed High-risk Brain Tumor * Study No.: K...
Detailed Description
Although significant progress has been made in the treatment of brain tumors, the prognosis remains dismal in patients with relapsed tumor. The outlook for infants and young children is also poor, pri...
Eligibility Criteria
Inclusion
- KSPNO-S-081: newly diagnosed embryonal brain tumor, age \>= 3 years
- KSPNO-S-082: all high-grade or malignant brain tumor, age \<3 years
- KSPNO-S-083: recurrent embryonal brain tumors, recurrent CNS germ cell tumor
Exclusion
- Patients with severe comorbid organ dysfunction (NCI grade \> 2 organ toxicity) prior to high-dose chemotherapy
- Patients with progressed tumor prior to high-dose chemotherapy
- Patients whose parents do not want to undergo high-dose chemotherapy and autologous stem cell rescue
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00798811
Start Date
September 1 2005
End Date
December 1 2021
Last Update
March 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea